Interaction of PD-L1 and PD-L2 ligands through binding to PD-1 receptors expressed on tumor-specific T cells initiate a negative signaling process downstream of PD-1, which reduces T cell activation and impairs tumor-killing function [11]. Here, PDCD1 is linked to neoplasm.